HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Dr. Vasan on Advancing the Treatment of Small HER2+ Breast Cancer

January 6th 2022

Neil Vasan, MD, discusses advances made in the treatment of patients with small HER2-positive breast cancer.

Tucatinib Triplet Maintains OS Benefit in HER2+ Breast Cancer With Brain Metastases

January 6th 2022

The combination of tucatinib, trastuzumab, and capecitabine continued to produce an improvement in overall survival compared with trastuzumab/capecitabine alone in patients with HER2-positive metastatic breast cancer who had stable or active brain metastases.

GlobalData Projects Continued Growth of HER2+ Breast Cancer Market

January 5th 2022

Driven by the anticipated launches of 5 pipeline agents and the label expansions of currently marketed drugs, theHER2-postive breast cancer market is expected to experience low growth from 2020 to 2030.

EMA Validates Type II Variation Application for Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

January 3rd 2022

The European Medicines Agency has validated the Type II Variation application for fam-trastuzumab deruxtecan-nxki as a treatment for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 1 or more anti–HER2-based regimens.

Dr. Rimawi on the Clinical Implications of the FeDeriCa Trial in Early-Stage HER2+ Breast Cancer

December 22nd 2021

Mothaffar Fahed Rimawi, MD, discusses the clinical implications of the phase 3 FeDeriCa trial in early-stage, HER2-positive breast cancer.

Japanese Approval Sought for Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

December 21st 2021

A supplemental new drug application has been submitted to Japan’s Ministry of Health, Labour, and Welfare or the use of fam-trastuzumab deruxtecan-nxki as a treatment in select patients with HER2-positive unresectable or recurrent breast cancer.

Dr. Hurvitz on the Key Objectives of DESTINY-Breast03 in HER2+ Breast Cancer

December 21st 2021

Sara A. Hurvitz, MD, discusses the rationale for the phase 3 DESTINY-Breast03 trial examining in HER2-positive breast cancer.

Investigators Parse a Crowded Third Line in Relapsed HER2-Positive Metastatic Breast Cancer

December 20th 2021

A panel of breast cancer experts shared their insights on 4 recently approved targeted therapies for patients with relapsed HER2-positive metastatic breast cancer.

Dr. Kimmick on Selecting Adjuvant Therapy for Patients With HER2+ Breast Cancer

December 16th 2021

Gretchen G. Kimmick, MD, MS, discusses selecting adjuvant therapy for patients with HER2-positive breast cancer.

Neoadjuvant Trastuzumab Deruxtecan Dosed in First Patient With Early-Stage HER2+ Breast Cancer

December 16th 2021

The first patient with high-risk, early-stage HER2-positive breast cancer has received a dose of neoadjuvant fam-trastuzumab deruxtecan-nxki as part of the global, phase 3 DESTINY-Breast11 trial.

Dr. Hurvitz on the Clinical Implications of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

December 14th 2021

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Dr. Fernandez on the Need to Refine Immunohistochemistry Testing in HER2+ Breast Cancer

December 14th 2021

Aileen I. Fernandez, PhD, discusses the need to refine immunohistochemistry testing in HER2-positive breast cancer.

Dr. Hurvitz on the Results of Subgroup Analyses From DESTINY-Breast03 in HER2+ Breast Cancer

December 9th 2021

Sara A. Hurvitz, MD, discusses the results of subgroup analyses from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

Efficacy of Pertuzumab/Trastuzumab Deruxtecan Combo Under Investigation in DESTINY-Breast09 for HER2+ Breast Cancer

December 9th 2021

Prior research has shown that the combination of trastuzumab deruxtecan plus pertuzumab may be superior to T-trastuzumab deruxtecan alone in patients with HER2-positive metastatic breast cancer and the combination is now under examination in the phase 3 DESTINY-Breast09 trial.

De-Escalated Approaches Continue to Show Benefit in HER2+ Breast Cancer

December 2nd 2021

Deborah L. Toppmeyer, MD, discusses clinical trials involving treatments for HER2-positive and triple-negative breast cancer, as well as the importance of making these trials accessible to all patient populations in an attempt to address disparities.

Dr. Vasan on Future Research Directions for Approved Agents in HER2+ Breast Cancer

November 23rd 2021

Neil Vasan, MD, PhD, discusses future research directions for approved agents used in the treatment of patients with HER2-positive breast cancer.

De-Escalation Approaches Lead Shift Away From Toxic Standards in HER2+ Breast Cancer

November 22nd 2021

Neil Vasan, MD, PhD, discussed the emergence of de-escalated treatment strategies for patients with HER2-positive breast cancer, pivotal trials that have shifted standards in clinical practice, and next steps for research.

Dr. Falkson on Opportunities for De-Escalating Therapy in HER2+ Breast Cancer

November 19th 2021

Carla Falkson, MBChB, MMed, MD, discusses opportunities for de-escalating therapy in patients with HER2-positive breast cancer.

Dr. Kimmick on the Evolving HER2+ Breast Cancer Treatment Paradigm

November 16th 2021

Gretchen G. Kimmick, MD, MS, discusses the quickly evolving treatment paradigm for patients with HER2-positive breast cancer.

Dr. Rimawi on Future Research Directions in Metastatic HER2+ Breast Cancer

November 11th 2021

Mothaffar Fahed Rimawi, MD, discusses future research directions in metastatic HER2-positive breast cancer.